Drug firm Neuland Laboratories Friday said it has received five observations from the US health regulator after inspection of Unit 1 of its facility at Bonthapally in Telangana.
The United States Food and Drug Administration (USFDA) inspected our Unit 1 manufacturing facility at Bonthapally from June 17 to 21, 2019 Neuland Laboratories said in a filing to BSE.
"The inspection has been completed with five observations given under form 483," it added.
The company has already initiated corrective and preventive actions for the observations and is confident of satisfying the FDA within the stipulated time, Neuland Laboratories said.
"This is a regular surveillance audit by USFDA, and no data integrity issues were observed during the inspection," it added.
The company, however, did not disclose the nature of the observations made by the US regulator.
Shares of Neuland Laboratories Friday ended at Rs 521.25 per scrip on the BSE, down 3.09 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app